June 14th, 2023 | 07:00 CEST
Evotec, Morphosys, Defence Therapeutics: Strong biotech stocks
When thinking of strong biotech stocks in recent years, BioNTech likely came to mind initially. With the successful development of the COVID-19 vaccine, the Mainz-based company advanced to become the new industry high-flyer. But in the meantime, the Company has come back to reality. The coffers are bulging, but vaccine revenues are falling, and the development of the cancer pipeline will still take several years. Therefore, Evotec and Morphosys are currently celebrating a comeback. Analysts are hailing Evotec as the "Tesla of biotech," and price targets are rising. The Morphosys share has increased by more than 100% this year, and analysts believe the value is capable of even more. Due to positive news, investors can speculate on a rebound with Defence Therapeutics.
time to read: 2 minutes | Author: Fabian Lorenz
ISIN: EVOTEC SE INH O.N. | DE0005664809 , DEFENCE THERAPEUTICS INC | CA24463V1013 , MORPHOSYS AG O.N. | DE0006632003
Table of contents:
Author
Fabian Lorenz
For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
Tag cloud
Shares cloud
Defence Therapeutics: Fighting pancreatic cancer
According to the Hirshberg Foundation for Pancreatic Cancer Research, pancreatic cancer has the highest mortality rate of all major cancers. The 5-year combined survival rate for all stages is only 12%. This is what Defence Therapeutics aims to change. Recently, the Canadian biotech has contracted Transbiotech Biotechnology Research and Transfer Center to begin testing its cellular anti-cancer ARM vaccine against deadly pancreatic cancer. This is not the first application of the vaccine. In vivo animal trials with solid T-cell lymphomas and melanomas have already been successfully completed. The results were very promising: 80% to 100% of the treated animals showed complete tumor regression.
If the results for pancreatic cancer are similarly positive, the share could take off again. Around the turn of the year, the Defence Therapeutics share more than tripled within a few weeks. From a high of EUR 3.20, it has corrected significantly in recent weeks and is now trading at EUR 1.68. Perhaps a second chance to get in? For the experts at researchanalyst.com, the biotech company is certainly exciting. From the analysts' perspective, Defence Therapeutics has several other irons in the fire. The exact details can be found in the study here.
Morphosys: Fresh analyst view causes euphoria
Morphosys shows how quickly the price of a biotech share can shoot up when the mood has turned. This year, the share price has more than doubled. For a long time, it was considered either the eternal bearer of hope or a hopeless case. But in the meantime, it is trading at EUR 27, and if UBS has its way, there is still much more to come. The analysts recommended the Morphosys share as a buy in their initial study. The price target is an impressive EUR 47. The current share price shows that the market has lost hope in Morphosys' drug pipeline and is only evaluating the sales of Monjuvi. The blood cancer drug Pelabresib alone has a sales potential of over USD 1 billion and is thus a potential blockbuster. From that, the UBS analysts calculated a net present value of EUR 35 per share.
JP Morgan is among the "hopeless". For their analysts, sales from the blood cancer drug Monjuvi are not developing as expected. Therefore, they rate Morphosys "Underweight" and see a price target of EUR 12. Deutsche Bank and Goldman Sachs also recommend the share with "Sell" and a price target of EUR 13 and EUR 12.50, respectively.
Evotec with a "Tesla moment"
Similar to Morphosys, Evotec has also gone through difficult times. The Hamburg-based company's shares are also looking good at the moment. After EUR 15 in December 2022, the share is now back at around EUR 23. The recent jump in the share price was triggered by Citigroup. For them, Evotec is the "Tesla of biologics manufacturers" and has enormous growth potential. The agreement with a subsidiary of the pharmaceutical giant Novartis, for example, has made the opportunities of the Evotec platform more concrete. The deal with the Novartis subsidiary would result in possible milestone payments of up to USD 640 million with low risks. Reason enough for Citi analysts to raise their price target for Evotec shares by 50% to EUR 31.60. Our colleagues at Warburg are similarly optimistic. They also recommend the Evotec share as a buy; the price target is EUR 30.
While BioNTech is currently out, the shares of Evotec and Morphosys are stepping on the gas. Defence Therapeutics shows that a correction can occur at any time. However, if the newsflow continues to be so positive, this share should also tend towards the old high again.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
